The legacy of Viagra and its originator, copyright, presents a complex picture for potential investors. While the iconic drug initially generated enormous earnings, its patent has expired , leading to competing versions flooding the arena. This decline in pricing presents a substantial hurdle for copyright and any fund considering a significant pos